Slide 1: This is Sobi
This is Sobi D Investor presentation July 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi key facts and business model 4 Latest results – Q2 2026 and business area update 18 Sustainability at Sobi 29 Pipeline and upcoming news flow 33 IR contacts 36 Notes 37 3
Slide 4: Sobi: Global biopharma company developing and commercialising rare disease therapies
Sobi: Global biopharma company developing and commercialising rare disease therapies Clear strategy with proven execution: • Identify: Successful BD track record building pipeline via partnerships and acquisitions • Unlock: Deep clinical-stage pipeline spanning multiple rare disease areas • Level Up
Slide 5: Business model
Business model Sobi is a global biopharma company unlocking Level up the potential of breakthrough therapies, transforming everyday life for people living with rare diseases. Level up access to life changing treatments Unlock Unlock best-in-class therapies Identify Identify unmet medical needs and b
Slide 6: Sobi has built a materially stronger financial platform over the last years
Sobi has built a materially stronger financial platform over the last years Revenue and Adj EBITA margin evolution 2020 - 2025 2020 – 2025 Finance performance Revenue (B SEK) Adj EBITA margin • Key investments made in 2021–2023 30 120 paying dividends in 2025 and 28 +12% at CER 26 beyond 22 • Delive
Slide 7: Globalising our footprint to increase access and impact
Globalising our footprint to increase access and impact Sobi revenues1, SEK bn Sobi territories2 – coverage of >90% of Global Mkt.3 US +11% >100 launches across Sobi territories 9.3 5.5 in last 5 years 2020 2025 Europe +7% 10.8 9 new 7.6 organisations since 2020, 2020 2025 e.g. Japan, International
Slide 8: Sobi is entering a unique moment of opportunity, with big launches and 5 potential blockbusters
Sobi is entering a unique moment of opportunity, with 6 big launches and 5 potential blockbusters Timeline 2024 2025 2026 2027 2028 2029 2030 Haemophilia A HLH / MAS C3G / IC-MPGN sHTG Uncontrolled gout NASP Progressive gout pozdeutinurad Joint health / synovitis1 VEXAS2 5 assets with block- Priorit
Slide 9: Doubling Sobi to 55bn SEK by 2030
With such opportunities ahead we are setting a new ambition: Doubling Sobi to 55bn SEK1 by 2030 Revenue, in SEK bn ILLUSTRATIVE ONLY, NOT TO SCALE 6 major launches 55 Altuvoct in HA Gamifant HLH/MAS Priority Portfolio development renewal programs through NASP in BD uncontrolled gout Gamifant in IDS
Slide 10: We will further scale internationally to drive growth and diversify the business
We will further scale internationally to drive growth and diversify the business Europe + North America Pint partnership as Share of Sobi business, in % of sales1 International move to further build LATAM presence • Established launch and 7% distribution platform for 16% >20% Sobi medicines • Accele
Slide 11: Leveraging our roots in rare disease and pivoting towards broader opportunities
Leveraging our roots in rare disease and pivoting towards broader opportunities The “Rare approach” remains at our Branching out from the rare core - examples core From To Deep scientific and medical foundation Patient-centric model built on long-term, pHLH IDS trusted physician partnerships Bra
Slide 12: Selected milestones and catalysts of the next years
Selected milestones and catalysts of the next years Status/ Peak sales Product Modality Indication Launch ambition Next milestones and catalysts Two modified SEK Launch in 16 countries in 2026-27; Haemophilia A Approved FREEDOM and SHINE data at EAHAD, FVIII biologics 10bn+ ISTH & ASH 2026 Mab targe
Slide 13: Next wave of catalysts driven by the innovative pipeline
Next wave of catalysts driven by the innovative pipeline Medicine Indication Phase 2 Phase 3 Registration Phase 4 Emapalumab Interferon-gamma driven sepsis (IDS)1 Balance high- Pacritinib VEXAS Syndrome confidence late-stage Chronic Myelomonocytic Leukemia (CMML)1 value with selective Myelofibrosis
Slide 14: Financial framework
Financial framework Track record Our ambition until 2030 Revenue (B SEK) R&D % of Sales Revenue growth to Top-line growth key contributor to SG&A % of Sales Adj EBITA Margin maintaining strong margins and operating 30 60 55bn SEK by 2030 leverage 28 26 R&D to remain 50 Depending on portfolio evoluti
Slide 15: Capital allocation strategy
Capital allocation strategy Fund Organic Maintain balance Continue Shareholder Growth (R&D and sheet strength disciplined value SGA expenses to and financial business drive launches) flexibility development Primary use of cash Strong operating Selective and Increasing is reinvestment in cash flows a
Slide 16: Sobi represents a compelling investment opportunity
We want to double Sobi to SEK 55bn revenue by 2030, 1 with sustained growth beyond Sobi represents a After a period of investment, we expect adjusted compelling investment 2 EBITA margins to return to the upper-30% range opportunity with a clear path to sustained long- term growth and value We will
Slide 17: Management Team
Management Team Management Team sobi.com/executive committee Executive committee | Sobi 17
Slide 18: Latest results Q2 2026 and business area update
Latest results Q2 2026 and business area update
Slide 19: Key takeaways for Q2 2026
Key takeaways for Q2 2026 Significant Q2 performance: +29% growth at CER and 35% adj. EBITA margin Aspaveli C3G / IC-MPGN continued early launch momentum Pozdeutinurad demonstrating meaningful urate reduction in REDUCE 2 NASP: CRL received on manufacturing with a clear path to resubmission Gamifant:
Slide 20: Strong growth of 29% at CER in Q2 delivered by our portfolio and across all regions
Strong growth of 29% at CER in Q2 delivered by our portfolio and across all regions Total net sales, SEK M, growth at CER Strategic portfolio, SEK M Revenue by region Doptelet 1 628 +36% Strategic1 +29% 7,842 Foundational Europe 3,207 +23% Altuvoct 1 554 +149% 6,175 Gamifant 794 +29% Aspaveli / Nort
Slide 21: Altuvoct: Continued expansion in Haemophilia A prophylaxis
Altuvoct: Continued expansion in Haemophilia A prophylaxis in our territory Haemophilia A sales SEK 2,256 M +41% Q2 Altuvoct: Best in class product • Continued strong momentum of Altuvoct • Growth at CER: +149% YoY, +20% QoQ • Launched in 30 countries, including key European markets Altuvoct launch
Slide 22: Aspaveli: Launch progressing across markets
Aspaveli: Launch progressing across markets, backed by new long-term and RWE data in C3G and IC-MPGN Aspaveli SEK 354 M Sustained launch momentum and expanding evidence base +18% Q2 • Continued expansion of Nephrology launch, and PNH remaining stable. UK approval in Q2; National reimbursement availa
Slide 23: Doptelet: Continues to deliver strong momentum globally
Doptelet: Continues to deliver strong momentum globally Doptelet SEK 1,628 M +36% Q2 Doptelet still accelerating as a high-growth global franchise • Doptelet’s differentiated profile – strong efficacy with fewer dietary restrictions – combined with excellent execution has established it as a leading
Slide 24: Gamifant HLH/MAS: US launch driving growth with strong momentum
Gamifant HLH/MAS: US launch driving growth with strong momentum Gamifant SEK 794 M +29% Q2 HLH/MAS launch • First-ever treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still's disease • Strong new patient demand continues to drive growth • Growth supported by Internatio
Slide 25: Gamifant IDS: Fastest path to patients discussed with EMA
Gamifant IDS: Fastest path to patients discussed with EMA’s Emergency Task Force Fast-to-market EMBRACE-II approach Phase 2b/3 randomised study – up to 1,800 patients planned • Aligning with EMA feedback Registration-enabling study design1 • Advancing with registrational Phase 2b/3 study in Europe H
Slide 26: Establishing Sobi as a leader in gout
Establishing Sobi as a leader in gout NASP • CRL: June 2026 relating to manufacturing NASP • No clinical safety or efficacy concerns were identified Uncontrolled that impact approvability SEK 4- gout 6bn • Resubmission planned in 6-12 months [15k patients]3 • Some launch cost shift to 2027 Progressi
Slide 27: Guidance upgrade: raising full-year guidance
Guidance upgrade: Strong HY performance across the portfolio leading us to raise full-year guidance Strong business performance Significant pipeline progress Revised Full Year 2026 in the first half of the year outlook 6 major ongoing or Outstanding HY growth of upcoming launches: 26% in CER Aspavel
Slide 28: Sobi Outlook 2026 - Updated
Sobi Outlook 2026 - Updated Key drivers for 2026 outlook - H1 update 2026 Updated Outlook • Progress with commercial portfolio and continued Altuvoct launch Revenue • H1 Growth 26% at CER Anticipated to grow by a mid-to • Critical investments in 2026 for future high-teens percentage at CER revenue g
Slide 29: Sustainability at Sobi
@sob! Sustainability at Sobi
Slide 30: Sustainability drives our strategic business priorities and decisions
Sustainability drives our strategic business priorities and decisions – progress Q2 2026 Patient commitment Responsible behaviour Main achievements Q2 2026 • Member of the 2026 Dow Jones Best in • Access to treatment • Safe and healthy work Class (DJ BIC) Index World & Europe • Patient centricity an
Slide 31: Commitment to patients
Commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity >53,000 people* treated with • Four international patient councils a Sobi medicine in 2025 to advise on early clinical development. • 525 employees completed training Co
Slide 32: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) A 77% reduction in CO2- intensity between 2016 and 95% Mean score 64 95% completed Code of 2023 (from 0,3 to 0,07 tonnes of Sobi’
Slide 33: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 34: Continued pipeline progress in Q2 2026
Continued pipeline progress in Q2 2026 Progressive gout Pozdeutinurad Positive topline data of REDUCE 2 (pivotal Phase 3) Uncontrolled gout NASP FDA Complete response letter – resubmission planned 2L in relapsed or refractory DLBCL Zynlonta LOTIS-5 combination study topline results Severe hypertrigl
Slide 35: Progress to be continued in 2026-27
Progress to be continued in 2026-27 Anticipated pipeline news flow 2026 H2 2027 Aspaveli – C3G & primary IC-MPGN Pozdeutinurad – Progressive gout o Japan regulatory decision o FDA submission Gamifant – HLH / MAS in Still’s disease NASP – Uncontrolled gout o Japan regulatory decision o FDA resubmissi
Slide 36: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com 36
Slide 37: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio, in the US. • Sobi has final developme
Slide 38: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com